Table 4 Study group characteristics—laboratory data.

From: Sex and other predictors of mortality in long-term follow-up of patients with cardiovascular disease and COVID-19: a single-center retrospective study

 

Whole group

(n = 4071)

Females

Males

P value

All

(n = 1888)

Survivors (n = 1739)

Nonsurvivors (n = 149)

P value

All

(n = 2183)

Survivors

(n = 1996)

Nonsurvivors (n = 187)

P value

Females vs. Males

CRP* (mg/l)

79.7 (78.6)

45.6 (12.1–96.1)

42.1 (10.6–90.1) a

77.6 (27.7–128.0)

 < 0.001

71.4 (29.8–125.0)

70.6 (28.7–125.0) a

79.6 (37.2–129.5)

0.07

 < 0.001

D-dimer* (mg/l)

3.2 (6.1)

1.2 (0.6–2.5)

1.1 (0.6–2.2)

2.3 (1.1–5.2)

 < 0.001

1.1 (0.6–2.8)

1.1 (0.6–2.5)

1.7 (0.9–4.5)

 < 0.001

0.82

Interleukin-6* (pg/ml)

88.0 (563.5)

25.1 (8.1–57.3)

23.8 (7.4–56.0) b

39.9 (21.6–78.8)

 < 0.001

33.3 (12.6–77.7)

32.2 (12.3–76.1) b

44.4 (19.5–90.8)

0.008

 < 0.001

NT-proBNP* (pg/ml)

2520.3 (15,904.2)

429.0 (154.0–1464.0)

365.0 (129.0–1073.0) c

2003.5 (666.0–5981.0)

 < 0.001

309.0 (110.0–1178.0)

266.0 (98.0–910.0) c

1488.5 (399.0–4494.0)

 < 0.001

 < 0.001

Troponin I* (ng/l)

194.6 (1662.0)

6.6 (2.9–17.9)

5.8 (2.7–13.9) d

22.7 (9.5–66.5)

 < 0.001

8.4 (3.9–23.3)

7.8 (3.7–19.0) d

22.9 (7.3–69.2)

 < 0.001

 < 0.001

eGFR**

(ml/min/1.73m2)

76.3 (30.2)

76.3 (58.4–92.1)

78.0 (61.6–93.1)

52.5 (30.5–76.3)e

 < 0.001

78.0 (61.0–93.9)

79.3 (64.8–94.6)

57.7 (40.3–85.4)e

 < 0.001

0.04

  1. *Maximal value during hospitalization.
  2. **Minimal value during hospitalization, estimated using MDRD formula.
  3. P value for comparisons of females vs. males among survivors: aP < 0.001, bP < 0.001, c P < 0.001; dP < 0.001;
  4. P value for comparisons of females vs. males among nonsurvivors: eP = 0.02.
  5. CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal pro B-type natriuretic peptide.
Back to article page